Skip to main content
logo
Coeptis Therapeutics Holdings, Inc. (COEP)
Apr 24, 2026 - COEP merged into ZSQR
16.40
+0.19 (1.17%)
Inactive · Last trade price on Apr 24, 2026

COEP Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.36---0.08
Revenue Growth
----143.81%
Cost of Revenue
0.18----
Gross Profit
1.18---0.08
Selling, General & Admin
10.735.6213.3534.1814.12
Research & Development
1.282.336.670.02-
Amortization of Goodwill & Intangibles
111--
Operating Expenses
14.2310.0521.4934.214.12
Operating Income
-13.04-10.05-21.49-34.2-14.05
Interest Expense
-0.64-0.46-0.11-0.22-0.19
Interest & Investment Income
0.120.23---
Other Non Operating Income (Expenses)
1.11-0.360.330.010.79
EBT Excluding Unusual Items
-12.46-10.64-21.27-34.41-13.45
Gain (Loss) on Sale of Investments
-0.09----
Gain (Loss) on Sale of Assets
-----0
Asset Writedown
--0.04---
Other Unusual Items
0.27-0.2--3.17-
Pretax Income
-12.28-10.88-21.27-37.57-13.45
Earnings From Continuing Operations
-12.28-10.88-21.27-37.57-13.45
Minority Interest in Earnings
0.360.2---
Net Income
-11.92-10.68-21.27-37.57-13.45
Net Income to Common
-11.92-10.68-21.27-37.57-13.45
Net Income Growth
-----
Shares Outstanding (Basic)
42111
Shares Outstanding (Diluted)
42111
Shares Change
120.03%49.84%79.70%30.98%79.11%
EPS (Basic)
-2.81-5.55-16.56-52.57-24.64
EPS (Diluted)
-2.81-5.55-16.56-52.57-24.64
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-8.6-6.65-7.24-3.88-4.49
Free Cash Flow Per Share
-2.03-3.46-5.64-5.42-8.23
Gross Margin
86.75%---100.00%
Operating Margin
-956.94%----18727.91%
Profit Margin
-874.29%----17932.37%
Free Cash Flow Margin
-631.16%----5985.92%
EBITDA
-11.86-9.05-20.49-33.19-13.6
D&A For EBITDA
1.181110.45
EBIT
-13.04-10.05-21.49-34.2-14.05
Revenue as Reported
1.36---0.08
SEC Filings: 10-K · 10-Q